Skip to content
Search
Please enter at least 3 characters.

Latest Stories

Survey: Total community pharmacy workforce drops 6 per cent in a year

The full-time equivalent community pharmacy workforce saw a 6 per cent decline in a year, while the overall number of pharmacists remains nearly constant, according to NHS England’s Community Pharmacy Workforce Survey 2022.

However, vacancy rates among pharmacists rose 16 percent, suggesting an increased reliance on locum pharmacists who, on average, work fewer hours, the data revealed.


According to NHSE, the mandated survey released (Aug. 3) achieved a 95 per cent completion rate among pharmacy contractors, marking a substantial increase compared to only 47 per cent in the previous year.

The survey results indicate a shift in working patterns within community pharmacy, with locum pharmacists being utilised more frequently as part of the staffing model.

The survey revealed a 6 per cent decrease in the community pharmacy workforce across all roles combined. The number of full-time equivalent pharmacists working in community pharmacy decreased by 2,411, from 20,255 in 2021 to 17,844 in 2022, the survey found.

The employed pharmacists decreased by 16 per cent from 12,774 in 2021 to 10,943 in 2022, while locum pharmacists increased by 26 per cent from 4,297 in 2021 to 5,477 in 2022, NHSE said.

However, the total headcount of community pharmacists remained 'almost constant' between 2021 and 2022, suggesting a trend of pharmacists working fewer hours in a community setting, it said.

Between autumn 2021, when the last survey was conducted, and autumn 2022, upon which these results are based, there was a significant 37 per cent increase in the number of reported independent prescribers (IPs) working within community pharmacy.

The survey indicated a potential shift in skills mix, showing a slight growth in the number of pharmacy technicians working as accuracy checkers, increasing from 2,368 in 2021 to 2,525 in 2022.

While there was an increase in the number of trainee dispensing assistants and medicines counter assistants, the survey indicated a reduction in the numbers of foundation pharmacists and pre-registration trainee pharmacy technicians.

The headcount of pre-registration pharmacy technicians working in community pharmacy declined from 957 in autumn 2021 to 793 in autumn 2022. The number of foundation pharmacists in community pharmacy decreased by 130 between autumn 2021 and autumn 2022, dropping from 1,583 to 1,453.

Shaping future investments

NHSE released the 2022 survey on Aug. 3, which follow the earlier release of the NHS Long Term Workforce Plan in June this year. There is an upcoming snapshot survey scheduled for autumn 2023.

The survey's insights are being utilised to shape future investments in education, training, and workforce planning across all sectors of pharmacy, NHSE said. "This includes an ongoing review of the impact of the Additional Roles Reimbursement Scheme (ARRS) and strategic planning for multidisciplinary roles in the future."

“Healthcare systems require high quality and transparent workforce data to plan and deliver safe care, improve patient outcomes, and inform staff training and development,” said Alan Ryan, National Director of Education at NHSE. “Following the publication of the first ever NHS Long Term Workforce Plan, the findings of the Community Pharmacy Workforce Survey are more important than ever.”

“The new requirement for a mandatory survey recognises the priority the NHS places on the community pharmacy workforce, and the importance of collecting consistent, accurate data to support effective workforce planning across primary care,” Ryan added.

“A wide range of work is being carried out by NHS England to develop the pharmacy professionals and the wider team members across all sectors of pharmacy. These emerging annual data sets will not only inform that work but will also help employers and workforce leads in Integrated Care Boards to build a picture of the whole pharmacy workforce in their locality,” he said.

CCA raises concerns 

The Company Chemist Association welcomed the results, acknowledging their significance in understanding the community pharmacy workforce's adaptability to meet evolving patient needs. However, the association expressed concern over potential data obsolescence, as the information cited in these findings was collected 10 months ago.

"Since the autumn of 2022, the situation in community pharmacy has continued to evolve," said Malcolm Harrison, Chief Executive of CCA. "Future surveys will require faster processing and publication to inform accurate decision-making effectively."

"The survey findings confirm what we have been saying for over a year, that pharmacist vacancy rates in community pharmacy have significantly increased since 2021," Harrison added. "Following the recent release of the NHS workforce plan, immediate action must be taken to address this growing problem."

CCA also raised concern about the 37 per cent increase in the number of Independent Prescribers. "We are concerned, however, that this does not reflect the whole picture,” he said. “The 37 per cent increase only accounts for a rise of 1.6 per cent in the total community pharmacist workforce, growing from 4.2 per cent to 5.8 per cent."

"We want to have 95 per cent of community pharmacists as prescribers by 2030. However, there is still a long way to go before the public can expect to find a prescriber in every pharmacy," Harrison said.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less